Drug Profile
IT 141
Alternative Names: IT-141; SN 38; SN-38 nanoparticles - Intezyne TechnologiesLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Intezyne
- Class Alkaloids; Anthracyclines; Antineoplastics; Camptothecins; Gene therapies; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Recurrent) in USA (IV, Infusion)
- 22 Jan 2021 IT 141 is still in phase I trials for Solid tumours in US
- 18 Dec 2020 Intezyne Technologies terminates phase I trial in Solid tumours (Recureent, Second line therapy or greater) in US (NCT03096340)